The Future of IBD Management: New Targets, Therapies, and Personalized Approaches

The Future of IBD Management: New Targets, Therapies, and Personalized Approaches

On-Demand Webcast

William J. Sandborn, MD, FACG
University of California San Diego
San Diego, California


Brian G. Feagan, MD, FACG
London Health Sciences Centre
Western University
London, Ontario

Bruce E. Sands, MD, MS, FACG
Icahn School of Medicine at Mount Sinai
New York, New York

Target Audience

This activity is intended for IBD specialists, gastroenterologists,GI fellows, and other healthcare professionals (internists, primary care physicians, nurse practitioners, physician assistants, nurses, pharmacists, etc) involved and/or interested in the therapeutic management of patients with IBD.


In recent years, treatment options for IBD have greatly expanded with the advent of new biologic agents with mechanisms of action that target various aspects of the inflammatory process. These medications can enable mucosal healing, slow or stop disease progression, and eliminate or reduce the need for steroid use. However, the need for new therapies and improved clinical strategies remains.

Personalized medicine will be required to achieve optimal outcomes in these patients. Predictive factors for severe disease course and nonresponse to treatment have been developed based on clinical studies. As more drug classes approved for the treatment of IBD become available, clinicians will need to consider multiple factors in the management of their IBD patients to preempt nonresponse and lost time in treatment.

In addition to anti-TNF medications, newer biologics with different mechanisms of action have been approved—the anti-α4 integrins, vedolizumab and natalizumab, and the interleukin (IL)-12/23 inhibitor, ustekinumab—that extend the options available to clinicians who treat patients with IBD. Several more medications for the treatment of IBD are in late-phase clinical trials. Clinicians need to fully understand the mechanisms of action and clinical usefulness of these new and emerging treatments for IBD.

The goal of this webcast is to provide gastroenterology professionals with expert guidance on the selection and use of newer targeted therapies for IBD and how to leverage implementation strategies for optimal clinical management and improved patient outcomes. Upon completion, learners should be better able to critically evaluate and interpret these newer treatment targets to make an informed, optimal therapeutic judgment in day-to-day clinical practice.


Upon successful completion of this educational activity, participants should be better able to:

  1. Develop personalized treatment strategies for patients with IBD based on predictive factors for severe disease course
  2. Identify molecular inflammatory targets of new and emerging agents for the treatment of IBD
  3. Summarize efficacy and safety data for novel IBD targeted therapies

Release Date: December 30, 2018

Expiration Date: December 30, 2019

Hardware/Software Requirements

The evaluation is accessible after the activity via a PC (Windows 7 or newer) or Mac (Mac OS 10.6 or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. Please direct technical questions to


Supported by an educational grant from: Celgene Corporation



Imedex is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


In support of improving patient care, this activity has been planned and implemented by North American Center for Continuing Medical Education (NACCME) and Imedex. NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.



Imedex designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credits™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.


NACCME has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 credit(s).

PAs should only claim credit commensurate with the extent of their participation.


This continuing nursing education activity awards 0.75 contact hours.

Provider approved by the California Board of Registered Nursing, Provider #13255 for 0.75 contact hours.


This knowledge-based activity (JA0006201-9999-19-013-H01-P) is approved for 0.75 contact hours (0.0075 CEUs) of continuing pharmacy education.

ACPE Credit Policy

Your official record of ACPE credit will be generated through the CPE Monitor System. The certificate printed from this website after completing the evaluation for this activity is for personal tracking purposes only.

Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended. Please note that you must complete the activity evaluation within 60 days of a live activity or within 60 days of beginning the evaluation for an enduring activity. Under ACPE Policy, NACCME will not be able to report your activity completion to CPE Monitor after this 60-day period.

Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity accredited by NACCME may contact the Manager, Accreditation & Compliance, NACCME, in writing at 104 Windsor Center Drive, East Windsor, NJ 08520. The Manager, Accreditation & Compliance will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Senior Director, Accreditation and Compliance, NACCME, may be made for a second level of review.

Planning Committee

The planning committee comprises Brian G. Feagan, MD, FACG, William J. Sandborn, MD, FACG, Bruce E. Sands, MD, MS, FACG; and Chris Bolwell, Manjusha Sala, Monalisa Singh and Susan Yarbrough, Imedex.

Financial Disclosure and Conflicts of Interest

According to the disclosure policy of NACCME and Imedex, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant financial relationships that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME and Imedex to initiate a mechanism to resolve any conflicts. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

Brian G. Feagan, MD, FACG has received research and/or grant support from Abbott, AbbVie, Amgen, AstraZeneca, Atlantic Pharmaceuticals Ltd., Boehringer- Ingelheim, Celgene Corporation, Celgene International, Celltech, Genentech Inc., Gilead Sciences Inc., GlaxoSmithKline, Hoffmann-La Roche Ltd., Janssen Research & Development LLC., Medimmune Ltd., Pfizer Inc., Receptos Inc., Sanofi, Santarus Inc., Takeda Development Center Americas Inc., Tillotts Pharma AG, and UCB Pharma, has served as a consultant for Abbott, AbbVie, Ablynx, Akebia Therapeutics, Allergan, Amgen, Applied Molecular Transport Inc., Aptevo Therapeutics, AstraZeneca, Atlantic Pharmaceuticals Ltd., Avaxia Biologics Inc., Avir Pharma, Baxter Healthcare Corp., Biogen Idec, Boehringer- Ingelheim, Bristol-Myers Squibb, Calypso Biotech, Celgene Corporation, Centocor Inc., Elan/Biogen, EnGene, Ferring Pharma, Galapagos, Genentech Inc., GiCare Pharma, Gilead Sciences Inc., Given Imaging Inc., GlaxoSmithKline, Inception IBD Inc., Ironwood Pharma, Janssen, Janssen Biotech, Johnson & Johnson, Kyowa Kakko Krin Co Ltd., Lexicon, Lilly, Lycera BioTech, Merck, Mesoblast Pharma, Millennium, Nektar, Nestles, Nextbiotix, Novartis, Novonordisk, Pfizer Inc., Prometheus Laboratories, Prometheus Therapeutics and Diagnostics, Progenity, Protagonist, Receptos Inc., Roche, Salix Pharma, Serono, Shire, Sigmoid Pharma, Sterna Biologicals, Synergy Pharma Inc., Takeda, Teva Pharma, TiGenix, Tillotts Pharma AG, UCB Pharma, Vertex Pharma, Vivelix Pharma, VHsquared Ltd., Warner-Chilcott, Wyeth, Zealand, and Zyngenia and has participated in a speaker's bureau for Abbott, AbbVie, Janssen, Johnson & Johnson, Lilly, Takeda, and UCB Pharma.

William J. Sandborn, MD, FACG has received research and/or grant support from AbbVie, Atlantic Pharmaceuticals, Boehringer-Ingelheim, Bristol-Myers Squibb, Genentech, Janssen, Nutrition Science Partners, Prometheus Laboratories, and Takeda and has served as a consultant for AbbVie, Actavis, Actogenix NV, Adherion Therapeutics, Akros Pharma, Ambrx Inc., Amgen, AM Pharma BV, Ardelyx Inc., AstraZeneca, Atlantic Pharmaceuticals, Arena Pharmaceuticals, Avaxia Biologics, Baxter Healthcare, Biogen, Boehringer-Ingelheim, Bristol-Myers Squibb, Catabasis Pharmaceuticals, Celgene, Celgene Cellular Therapeutics, Chiasma, Cosmo Pharmaceuticals, Eisai, Eli Lilly, Ferring Pharmaceuticals, Ferring Research Institute, Forward Pharma, Galapagos, Genentech, Gilead Sciences, Immune Pharmaceuticals, Index Pharmaceuticals, Ironwood Pharmaceuticals, Janssen, Kyowa Hakko Kirin, Lexicon Pharmaceuticals, Lipid Therapeutics Gmbh, Luitpold Pharmaceuticals, Medimmune, Mesoblast Inc., Millennium Pharmaceuticals, Nestle, Novo Nordisk, Nutrition Science Partners, Orexigen, Palatin, Prometheus Laboratories, Qu Biologics, Regeneron, Ritter Pharmaceuticals, Salix Pharmaceuticals, Santarus, Seattle Genetics, Seres Health, Shire, Sigmoid Biotechnologies, Takeda, Teva Pharmaceuticals, Theravance, TiGenix, Tillotts Pharma, Toray Industries Inc., UCB Pharma, Western University, Vascular Biogenics, Vertex Pharmaceuticals, Warner Chilcott, August Wolff, and Zyngenia.

Bruce E. Sands, MD, MS, FACG has served as a consultant for AbbVie, Allergan Sales, Amgen, Boehringer-Ingelheim, Celgene, Cowen Services Company, LLC, Janssen Biotech, Lilly, Pfizer, Rockpointe, Inc., Shire, Synergy Pharmaceuticals, Takeda, TargetPharmasolutions, Theravance Biopharma R&D, TiGenix, and UCB and has participated in a speaker's bureau for American Gastroenterological Association, American College of Gastroenterology, Columbia University, Imedex, MCV Foundation, New York Methodist Hospital, University of Washington, Vindico Medical Education, and Yale University.

Chris Bolwell discloses that he holds shares of stock of GlaxoSmithKline.

Manjusha Sala, Monalisa Singh and Susan Yarbrough disclosed no relevant financial relationships with any commercial interests.


This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the European Medicines Agency (EMA) of the European Union or the Food and Drug Administration (FDA) of the United States. Participants are strongly encouraged to consult approved product labeling for any drug or device mentioned in this activity before use. The opinions expressed during this activity are the opinions of the respective authors, presenters or moderators and do not necessarily reflect the opinions of NACCME or Imedex.

Privacy Policy

NACCME and Imedex protect the privacy of personal and other information regarding participants, educational partners, and joint providerss. NACCME, Imedex and our joint providers will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

NACCME and Imedex maintain physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2018 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education. The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.